[go: up one dir, main page]

MX2019008435A - Inhibidores selectivos de jak1. - Google Patents

Inhibidores selectivos de jak1.

Info

Publication number
MX2019008435A
MX2019008435A MX2019008435A MX2019008435A MX2019008435A MX 2019008435 A MX2019008435 A MX 2019008435A MX 2019008435 A MX2019008435 A MX 2019008435A MX 2019008435 A MX2019008435 A MX 2019008435A MX 2019008435 A MX2019008435 A MX 2019008435A
Authority
MX
Mexico
Prior art keywords
selective jak1
jak1 inhibitors
compounds
formula
disclosed
Prior art date
Application number
MX2019008435A
Other languages
English (en)
Other versions
MX390625B (es
Inventor
Juhani Lepistö Matti
Birgitta Margareta Åstrand Annika
Grant Kettle Jason
Magnus Nilsson Karl
Ingrid Kristina Berggren Anna
R Johansson Johan
Pralhad Kawatkar Sameer
Su Qibin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019008435A publication Critical patent/MX2019008435A/es
Publication of MX390625B publication Critical patent/MX390625B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se desvelan en el presente documento compuestos de Fórmula (I), (ver formula) y sales farmacéuticamente aceptables de los mismos, en la que R1-R8 tienen cualquiera de los significados definidos en el presente documento. Además, se desvelan composiciones farmacéuticas que comprenden compuestos de Fórmula (I) y métodos de uso de los mismos.
MX2019008435A 2017-01-17 2018-01-16 Inhibidores selectivos de jak1. MX390625B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447057P 2017-01-17 2017-01-17
PCT/EP2018/051038 WO2018134213A1 (en) 2017-01-17 2018-01-16 Jak1 selective inhibitors

Publications (2)

Publication Number Publication Date
MX2019008435A true MX2019008435A (es) 2019-09-09
MX390625B MX390625B (es) 2025-03-19

Family

ID=61024756

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022002976A MX418519B (es) 2017-01-17 2018-01-16 Inhibidores selectivos de jak1
MX2019008435A MX390625B (es) 2017-01-17 2018-01-16 Inhibidores selectivos de jak1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022002976A MX418519B (es) 2017-01-17 2018-01-16 Inhibidores selectivos de jak1

Country Status (39)

Country Link
US (3) US10961228B2 (es)
EP (2) EP3571192B1 (es)
JP (3) JP6986086B2 (es)
KR (2) KR102659213B1 (es)
CN (2) CN115925693B (es)
AR (1) AR110753A1 (es)
AU (1) AU2018209667B2 (es)
CA (1) CA3049175A1 (es)
CL (1) CL2019001993A1 (es)
CO (1) CO2019007888A2 (es)
CR (1) CR20190332A (es)
DK (1) DK3571192T3 (es)
DO (1) DOP2019000184A (es)
EA (1) EA037067B1 (es)
EC (1) ECSP19051352A (es)
ES (1) ES2938648T3 (es)
FI (1) FI3571192T3 (es)
HR (1) HRP20230069T1 (es)
HU (1) HUE061064T2 (es)
IL (1) IL267851B (es)
JO (1) JOP20190174B1 (es)
LT (1) LT3571192T (es)
MA (1) MA47301B1 (es)
MX (2) MX418519B (es)
MY (1) MY199735A (es)
NI (1) NI201900077A (es)
NZ (1) NZ756069A (es)
PE (1) PE20191108A1 (es)
PH (1) PH12019501639B1 (es)
PL (1) PL3571192T3 (es)
PT (1) PT3571192T (es)
RS (1) RS63981B1 (es)
SG (1) SG11201906222WA (es)
SI (1) SI3571192T1 (es)
SM (1) SMT202300051T1 (es)
TW (1) TWI753089B (es)
UA (1) UA124246C2 (es)
WO (1) WO2018134213A1 (es)
ZA (1) ZA201906875B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6986086B2 (ja) * 2017-01-17 2021-12-22 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Ｊａｋ１選択的阻害剤
EP3789386A1 (en) * 2017-01-26 2021-03-10 Hanmi Pharm. Co., Ltd. Pyrimidine compound and pharmaceutical use thereof
EP3823964A1 (en) * 2018-07-18 2021-05-26 Astrazeneca AB A xinafoate salt of a jak inhibiting compound
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US12234232B2 (en) 2018-09-21 2025-02-25 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
BR112021020964A2 (pt) * 2019-04-19 2021-12-14 Dizal Jiangsu Pharmaceutical Co Ltd Inibidor seletivo de quinase jak1
MX2021015724A (es) 2019-06-27 2022-05-16 Hanmi Pharm Ind Co Ltd Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
JP7478252B2 (ja) 2020-04-09 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
EP4253375B1 (en) * 2020-11-26 2026-01-07 Artivila (ShenZhen) Innovation Center, Ltd. Amide compound, pharmaceutical composition and use thereof
KR20230154436A (ko) * 2021-02-26 2023-11-08 타이라 바이오사이언시스, 인크. 아미노피리미딘 화합물 및 그의 사용 방법
US12240836B2 (en) * 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
WO2024150110A1 (en) * 2023-01-11 2024-07-18 Pfizer Inc. Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN115974845B (zh) * 2023-01-19 2024-09-20 奥锐特药业股份有限公司 奥希替尼中间体的制备方法
AU2024236890A1 (en) * 2023-03-16 2025-09-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
GB202316063D0 (en) 2023-10-20 2023-12-06 Astrazeneca Ab Dosing regime
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580913A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
US20100204282A1 (en) 2007-02-05 2010-08-12 Hutchinson John H Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009045700A2 (en) 2007-10-05 2009-04-09 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
BR112013006016A2 (pt) * 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
CN111848586B (zh) * 2015-09-25 2024-05-03 迪哲(江苏)医药股份有限公司 用于抑制jak的化合物和方法
JP6986086B2 (ja) 2017-01-17 2021-12-22 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Ｊａｋ１選択的阻害剤

Also Published As

Publication number Publication date
IL267851B (en) 2021-08-31
BR112019014526A2 (pt) 2020-02-27
IL267851A (en) 2019-09-26
US11897869B2 (en) 2024-02-13
EP4219470A1 (en) 2023-08-02
HRP20230069T1 (hr) 2023-03-17
JOP20190174B1 (ar) 2023-09-17
US20190367490A1 (en) 2019-12-05
AU2018209667B2 (en) 2020-05-07
UA124246C2 (uk) 2021-08-11
WO2018134213A1 (en) 2018-07-26
ES2938648T3 (es) 2023-04-13
KR20190104215A (ko) 2019-09-06
MX418519B (es) 2024-12-09
FI3571192T3 (fi) 2023-03-06
CR20190332A (es) 2019-09-13
ZA201906875B (en) 2021-05-26
PE20191108A1 (es) 2019-08-26
EP3571192A1 (en) 2019-11-27
TW201838984A (zh) 2018-11-01
CN110461830B (zh) 2022-11-01
CO2019007888A2 (es) 2019-07-31
MA47301B1 (fr) 2023-02-28
MX2022002976A (es) 2022-04-06
HUE061064T2 (hu) 2023-05-28
KR20230141938A (ko) 2023-10-10
TWI753089B (zh) 2022-01-21
EA037067B1 (ru) 2021-02-02
PH12019501639B1 (en) 2023-09-08
US12473272B2 (en) 2025-11-18
JP7626819B2 (ja) 2025-02-04
CN115925693A (zh) 2023-04-07
NZ756069A (en) 2025-08-29
US20240208947A1 (en) 2024-06-27
US20210188821A1 (en) 2021-06-24
EA201991700A1 (ru) 2020-01-28
LT3571192T (lt) 2023-02-27
MX390625B (es) 2025-03-19
PL3571192T3 (pl) 2023-03-20
PH12019501639A1 (en) 2020-07-06
CN110461830A (zh) 2019-11-15
CN115925693B (zh) 2024-11-12
EP3571192B1 (en) 2022-11-30
JOP20190174A1 (ar) 2019-07-14
JP2022043059A (ja) 2022-03-15
JP6986086B2 (ja) 2021-12-22
NI201900077A (es) 2020-03-18
AR110753A1 (es) 2019-05-02
DOP2019000184A (es) 2019-08-15
KR102659213B1 (ko) 2024-04-18
CL2019001993A1 (es) 2019-12-27
SG11201906222WA (en) 2019-08-27
CA3049175A1 (en) 2018-07-26
JP7394820B2 (ja) 2023-12-08
JP2024010041A (ja) 2024-01-23
PT3571192T (pt) 2023-02-21
JP2020506171A (ja) 2020-02-27
SI3571192T1 (sl) 2023-03-31
DK3571192T3 (da) 2023-02-06
US10961228B2 (en) 2021-03-30
KR102585048B1 (ko) 2023-10-05
RS63981B1 (sr) 2023-03-31
ECSP19051352A (es) 2019-07-31
MY199735A (en) 2023-11-21
SMT202300051T1 (it) 2023-03-17
MA47301A (fr) 2019-11-27
AU2018209667A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MX2019008435A (es) Inhibidores selectivos de jak1.
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
EA201691302A1 (ru) Новые гетероциклические соединения
MX2020007265A (es) Derivados de rapamicina.
EA201991884A2 (ru) Ингибиторы g12c kras
MX383935B (es) Amidas heterocíclicas como inhibidores de cinasa.
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
JO3654B1 (ar) مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201690127A1 (ru) Состав на основе ингибиторов syk
MX381994B (es) Inhibidor de janus quinasa.
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX390051B (es) Antagonistas de ep4.
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
JOP20190163B1 (ar) منشط nrf2
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA201792676A1 (ru) Ингибиторы jak1